By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > NSAID > Meloxicam

Meloxicam

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|639 words

Meloxicam Drug Profile

What is Meloxicam?

Meloxicam is a prescription anti-inflammatory medication belonging to the class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). It is primarily used to reduce pain, swelling, and stiffness associated with arthritis and other inflammatory conditions. As a selective COX-2 inhibitor, meloxicam is designed to provide anti-inflammatory benefits while potentially causing fewer gastrointestinal side effects than traditional NSAIDs.

Uses

Meloxicam is approved for several inflammatory conditions:

  • Osteoarthritis: Reduces joint pain and stiffness in the most common form of arthritis affecting weight-bearing joints
  • Rheumatoid arthritis: Helps manage inflammation and pain in this autoimmune condition that affects multiple joints
  • Juvenile idiopathic arthritis: Treats inflammation in children and adolescents with this form of childhood arthritis
  • Ankylosing spondylitis: Manages pain and stiffness in this inflammatory condition primarily affecting the spine
  • Acute pain conditions: Sometimes prescribed for short-term relief of moderate pain from injuries or minor surgical procedures

How it works

Meloxicam works by blocking cyclooxygenase (COX) enzymes, particularly COX-2, which are responsible for producing prostaglandins—chemicals that cause inflammation, pain, and fever in the body. By reducing prostaglandin production, meloxicam decreases inflammation and provides pain relief. Its selective inhibition of COX-2 over COX-1 is designed to maintain anti-inflammatory effects while preserving some protective functions in the digestive system.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Stomach upset or nausea
  • Diarrhea or constipation
  • Dizziness
  • Headache
  • Fluid retention and swelling
  • Increased blood pressure
  • Upper respiratory tract infections
  • Skin rash

Serious side effects requiring immediate medical attention:

  • Signs of stomach bleeding (black stools, vomiting blood)
  • Severe allergic reactions (difficulty breathing, facial swelling)
  • Heart attack or stroke symptoms
  • Kidney problems (changes in urination, swelling)
  • Severe skin reactions (blistering, peeling)

Warnings and precautions

  • Cardiovascular risk: Meloxicam may increase the risk of heart attack and stroke, especially with long-term use or in patients with existing heart disease
  • Gastrointestinal bleeding: Can cause stomach ulcers and bleeding, particularly in elderly patients or those with a history of peptic ulcer disease
  • Kidney function: Should be used cautiously in patients with kidney disease, as NSAIDs can worsen kidney function and cause fluid retention
  • Pregnancy considerations: Not recommended during pregnancy, especially in the third trimester, as it may harm the developing fetus and interfere with labor
  • Elderly patients: Require lower doses and careful monitoring due to increased risk of side effects

Interactions

Meloxicam can interact with several medications:

  • Warfarin and blood thinners: Increases bleeding risk when combined with anticoagulant medications
  • ACE inhibitors and ARBs: May reduce the effectiveness of these blood pressure medications and increase kidney toxicity risk
  • Lithium: Can increase lithium levels in the blood, potentially causing toxicity
  • Methotrexate: May increase methotrexate toxicity by reducing its elimination from the body
  • Aspirin: Combining with aspirin may increase gastrointestinal bleeding risk and reduce cardioprotective benefits
  • Diuretics: May reduce the effectiveness of water pills and increase kidney problems
  • Other NSAIDs: Should not be combined with other anti-inflammatory drugs due to increased side effect risk
  • Cyclosporine: May increase kidney toxicity when used together

Check interactions with the GMJ Interaction Checker

Dosage

Adult dosages typically range from 7.5 mg to 15 mg taken once daily, depending on the condition being treated and patient response. For osteoarthritis, the usual starting dose is 7.5 mg once daily, which may be increased to 15 mg if needed. For rheumatoid arthritis, the recommended dose is 7.5 mg once daily, with a maximum of 15 mg daily. The lowest effective dose should always be used for the shortest duration necessary to control symptoms. Dosage adjustments may be required for elderly patients or those with kidney or liver problems. Always follow your healthcare provider’s specific dosing instructions, as individual needs may vary based on medical history and response to treatment.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Meloxicam." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/meloxicam/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Pediatric influenza hospitalizations nearly doubled post-pandemic, Canadian surveillance finds

Canadian surveillance study reveals pediatric influenza hospitalizations nearly doubled in 2022–2023, with…

Trump’s Perfect Cognitive Test Score: What Montreal Cognitive Assessment Really Measures

President Trump's perfect 30/30 score on cognitive testing prompts medical experts to…

Breakthrough Drug Targeting ‘Undruggable’ KRAS Mutation Nearly Doubles Pancreatic Cancer Survival

New targeted therapy daraxonrasib successfully inhibits KRAS mutations in pancreatic cancer, nearly…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Ibuprofen

By
Prof. Giorgi Pkhakadze
02/06/2026

Diclofenac

By
Prof. Giorgi Pkhakadze
02/06/2026

Etoricoxib

By
Prof. Giorgi Pkhakadze
02/06/2026

Ketorolac

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up